• Bahadur N, Leathart JBS, Mutch E et al. (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochemical Pharmacology 64, 15791589.
  • Cavaco I, Strömberg-Nörklit J, Kaneko A et al. (2005) CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. European Journal of Clinical Pharmacology 61, 1518.
  • Clarke JB, Maggs JL, Kitteringham NR & Park BK (1990) Immunogenicity of amodiaquine in the rat. International Archives of Allergy and Applied Immunology 91, 335342.
  • Dai D, Zeldin DC, Blaisdell JA et al. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597607.
  • Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental & Clinical Pharmacology 17, 2741.
  • Ehrhardt S, Mockenhaupt FP, Agana-Nsiire P et al. (2002) Efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria in northern Ghana. Annals of Tropical Medicine and Parasitology 96, 239247.
  • Harrison AC, Kitteringham NR, Clarke JB & Park BK (1992) The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochemical Pharmacology 43, 14211430.
  • Heubi JE, Barbacci MB & Zimmerman HJ (1998) Therapeutic misadventures with acetaminophen: hepatotoxicity after multiple doses in children. Journal of Pediatrics 132, 2227.
  • Li X-Q, Björkman A, Andersson TB, Ridderström M & Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. The Journal of Pharmacology and Experimental Therapeutics 300, 399407.
  • Li X-Q, Björkman A, Andersson TB, Gustafsson LL & Masimirembwa MC (2003) Identification of human cytochrome P 450's that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. European Journal of Clinical Pharmacology 59, 429442.
  • Low DA & Smith A (1976) History of East Africa. Oxford University Press, Oxford, pp. 576577.
  • Mitchell JR, Jollow DJ, Potter WZ, Gillette JR & Brodie BB (1973) Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. The Journal of Pharmacology and Experimental Therapeutics 187, 211217.
  • Mockenhaupt FP, Ehrhardt S, Gellert S et al. (2004) Alpha(+)-thalassemia protects African children from severe malaria. Blood 104, 20032006.
  • Mockenhaupt FP, Ehrhardt S, Dzisi SY et al. (2005) A randomised, placebo-controlled, and double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Tropical Medicine and International Health 10, 512520.
  • Naisbitt DJ, Williams DP, O'Neill PM et al. (1998) Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chemical Research in Toxicology 11, 15861595.
  • Niagia S (2004) Ghana battles drug-resistant malaria with artesunate. Lancet 363, 1372.
  • O'Neill PM, Mukhtar A, Stocks PA et al. (2003) Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. Journal of Medicinal Chemistry 46, 49334945.
  • Oduro AR, Anyorigiya T, Hodgson A et al. (2005) A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Tropical Medicine and International Health 10, 279284.
  • Olliaro P, Nevill C, LeBras J et al. (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348, 11961201.
  • Phillips-Howard PA & West LJ (1990) Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of the Royal Society of Medicine 83, 8285.
  • Weise A, Grundler S, Zaumsegel D et al. (2004) Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clinical Laboratory 50, 141148.
  • WHO (2001) Antimalarial Drug Combination Therapy. Report of a WHO technical consultation. (WHO/CDS/RBM/2001.35) WHO, Geneva.